Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11889609 | 0.93 | TSHR (0.34) | TSHR | |
| SCHEMBL17807212 | 0.83 | ABCB11 (0.38) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL5775390 | 0.80 | ABCB11 (0.33) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL9937822 | 0.74 | TSHR (0.41) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| Ammonia Solution, Strong SCHEMBL27732666 | 0.73 | TSHR (0.39) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| Fluoromethane SCHEMBL27913775 | 0.71 | CA2 (0.41) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| Methyl Alcohol SCHEMBL9063376 | 0.71 | MEN1 (0.41) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL23647292 | 0.71 | CA2 (0.44) | CYP3A4TSHRCA2 | |
| SCHEMBL10835191 | 0.71 | CA2 (0.44) | CYP3A4TSHRCA2 | |
| SCHEMBL299301 | 0.71 | CA2 (0.44) | CYP3A4TSHRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | claimed |
| JP-4338974-B2 | — | — | 2009-10-07 | — | — | JP | claimed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | claimed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | claimed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | claimed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | claimed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | claimed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | claimed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | claimed |
| JP-2004527499-A | — | — | 2004-09-09 | — | — | JP | claimed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | claimed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | claimed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | claimed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ABCB11 391/4885CYP3A4 373/4885ADRA2B 140/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | ABCB11 484/4885CYP3A4 67/4885ADRA2B 381/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ABCB11 871/4885CYP3A4 207/4885ADRA2B 273/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | ABCB11 484/4885CYP3A4 67/4885ADRA2B 381/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | ABCB11 351/4885CYP3A4 385/4885ADRA2B 221/4885 |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | ABCB11 1836/4885CYP3A4 508/4885ADRA2B 2313/4885 |
| US-20020147198-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | ABCB11 484/4885CYP3A4 67/4885ADRA2B 381/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | ABCB11 351/4885CYP3A4 385/4885ADRA2B 221/4885 |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | FLT1, FLT4, NAT1 | ABCB11 316/4885CYP3A4 182/4885ADRA2B 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.